Brain proteomic changes by histone deacetylase inhibition after traumatic brain injury

BACKGROUND: Traumatic brain injury (TBI) is a leading cause of morbidity and mortality. There are currently no cytoprotective treatments for TBI. There is growing evidence that the histone deacetylase inhibitor valproic acid (VPA) may be beneficial in the treatment of TBI associated with hemorrhagic...

Descripción completa

Detalles Bibliográficos
Autores principales: Pumiglia, Luke, Williams, Aaron M, Kemp, Michael T, Wakam, Glenn K, Alam, Hasan B, Biesterveld, Ben E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993337/
https://www.ncbi.nlm.nih.gov/pubmed/33880414
http://dx.doi.org/10.1136/tsaco-2021-000682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993337/
https://www.ncbi.nlm.nih.gov/pubmed/33880414
http://dx.doi.org/10.1136/tsaco-2021-000682

Ejemplares similares